Navigation Links
Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
Date:10/30/2012

MONTREAL, Oct. 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has decided to reschedule its webcast and conference call to discuss financial results for the 2012 third quarter, which was previously scheduled for Wednesday, October 31, 2012 at 8 a.m. ET, due to the severe weather conditions and power outages associated with Hurricane Sandy. The webcast and conference call has been rescheduled for November 2, 2012 at 8 a.m. ET and the financial results will be issued at 6:00 a.m. ET.

The dial-in number to participate on this call is (877) 281-0402, confirmation code 39252322.  International callers should dial (631) 813-4869, confirmation code 39252322. A replay will be available approximately two hours following the conclusion of the conference call to Friday, November 9, 2012, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 39252322.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
2. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
3. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
4. Valeant Pharmaceuticals To Syndicate Incremental Loans
5. Valeant Pharmaceuticals Announces Management Change
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
8. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
9. Valeant Pharmaceuticals To Host Investor Day
10. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
11. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
Breaking Medicine Technology:
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , the ... This new addition to the Mirroring360 product family combines device screen mirroring with ... Pro enables educators, business professionals and individuals to stream or mirror app screens, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
Breaking Medicine News(10 mins):